The Journal of Pathology · 2014 · 40 citations · 40 references
MedicineMolecular BiologyOncologyGene ExpressionMolecular OncologyOncogenesCancer ProgressionMalignant TumorsProto-oncogene ActivationSoft Tissue SarcomasTranscription Factor OncogenesTumor InvasionC-jun N-terminal Kinase SignalingCell Cycle DynamicsDedifferentiated LiposarcomaG1 Phase ProgressionG1-s Phase TransitionJun OncogenesOncogene Expression AnalysisOncogene Regulation
Genomic amplification of the c-Jun proto-oncogene has been identified in ∼30% of dedifferentiated liposarcomas (DDLPS), but the functional contribution of c-Jun to the progression of DDLPS remains poorly understood. In previous work we showed that knock-down of c-Jun by RNA interference impaired the in vitro proliferation and in vivo growth of a DDLPS cell line (LP6) with genomic amplification of the c-Jun locus. Here, we used gene expression analysis and functional studies in a broad panel of cell lines to further define the role of c-Jun in DDLPS and other soft tissue sarcomas. We show that c-Jun knock-down impairs transition through the G1 phase of the cell cycle in multiple DDLPS cell lines. We also found that high levels of c-Jun expression are both necessary and sufficient to promote DDLPS cell migration and invasion in vitro. Our data suggest that high levels of c-Jun enhance motility in part by driving the expression of ENPP2/Autotaxin. c-Jun over-expression has minimal effects on in vitro proliferation but substantially enhances the in vivo growth of weakly tumourigenic DDLPS cell lines. Finally, we provide evidence that c-Jun genomic amplification and over-expression may have similar functional consequences in other types of soft tissue sarcoma. Our data suggest a model in which relatively low levels of c-Jun are sufficient for in vitro proliferation, but high levels of c-Jun enhance invasiveness and capacity for in vivo tumour growth. These observations provide an explanation for the selective advantage provided by c-Jun genomic amplification in vivo and suggest that sarcomas with elevated c-Jun levels are likely to have a particularly high malignant potential. Data from exon array and RNA-Seq experiments have been deposited in the GEO database (Accession No. GSE57531).
40
The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1
Peter Angel, Kazue Hattori, Tod Smeal et al. · Cell · 1988 · 1.3K citations
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Jordi Barretina, Barry S. Taylor, Shantanu Banerji et al. · Nature Genetics · 2010 · 726 citations · Full text
Walter H. Henricks, Young Chae Chu, John R. Goldblum et al. · The American Journal of Surgical Pathology · 1997 · 623 citations
Control of cell cycle progression by c-Jun is p53 dependent
Martin Schreiber, Andrea Kolbus, Fabrice Piu et al. · Genes & Development · 1999 · 576 citations · Full text